Objective To present a summary of the 2020 version of the European Association of Urology
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …

Investigations into the interaction between radiotherapy and the host immune system have
uncovered new mechanisms that can potentially be exploited to improve the efficacy of …

Background Innovations in treatments, imaging, and molecular characterisation in advanced
prostate cancer have improved outcomes, but there are still many aspects of management …

Background Adjuvant radiotherapy reduces the risk of biochemical progression in prostate
cancer patients after radical prostatectomy. We aimed to compare adjuvant versus early …

Objective To present a summary of the 2016 version of the European Association of Urology
(EAU)-European Society for Radiotherapy & Oncology (ESTRO)-International Society of …

Approximately 15% of patients with prostate cancer are diagnosed with high-risk disease.
However, the current definitions of high-risk prostate cancer include a heterogeneous group …

Background We did a randomised phase 3 trial assessing the benefit of addition of long-
term androgen suppression with a luteinising-hormone-releasing hormone (LHRH) agonist …

Importance There is a clear need for a molecular subtyping approach in prostate cancer to
identify clinically distinct subgroups that benefit from specific therapies. Objectives To …

Background It is not known whether short-term androgen-deprivation therapy (ADT) before
and during radiotherapy improves cancer control and overall survival among patients with …

Background The combination of radiotherapy plus long-term medical suppression of
androgens (≥ 2 years) improves overall survival in patients with locally advanced prostate …